Zacks Research Has Positive Outlook for Novartis Q1 Earnings

Novartis AG (NYSE:NVS - Free Report) - Equities research analysts at Zacks Research upped their Q1 2026 earnings per share estimates for Novartis in a report issued on Tuesday, June 24th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings of $2.28 per share for the quarter, up from their prior estimate of $2.24. The consensus estimate for Novartis' current full-year earnings is $8.45 per share. Zacks Research also issued estimates for Novartis' Q2 2026 earnings at $2.38 EPS, Q4 2026 earnings at $2.20 EPS, FY2026 earnings at $9.10 EPS, Q1 2027 earnings at $2.38 EPS and FY2027 earnings at $9.63 EPS.

Novartis (NYSE:NVS - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported $2.28 EPS for the quarter, beating the consensus estimate of $2.12 by $0.16. The firm had revenue of $13.23 billion during the quarter, compared to the consensus estimate of $12.92 billion. Novartis had a net margin of 24.70% and a return on equity of 39.44%. Novartis's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.80 EPS.

Separately, BNP Paribas raised Novartis to a "strong-buy" rating in a report on Tuesday, April 15th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, one has given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $123.38.

Novartis Trading Down 0.8%

Shares of Novartis stock opened at $117.93 on Thursday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.61 and a current ratio of 0.79. The company has a market capitalization of $249.12 billion, a P/E ratio of 18.43, a PEG ratio of 1.71 and a beta of 0.59. Novartis has a 1 year low of $96.06 and a 1 year high of $120.92. The company's fifty day moving average is $113.57 and its two-hundred day moving average is $107.81.

Institutional Trading of Novartis

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Brighton Jones LLC increased its position in Novartis by 76.5% during the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company's stock worth $599,000 after purchasing an additional 2,666 shares during the period. Union Bancaire Privee UBP SA acquired a new stake in shares of Novartis in the 4th quarter valued at approximately $27,000. IFP Advisors Inc boosted its stake in shares of Novartis by 25.7% in the fourth quarter. IFP Advisors Inc now owns 1,730 shares of the company's stock valued at $168,000 after buying an additional 354 shares in the last quarter. Crestwood Advisors Group LLC grew its holdings in Novartis by 9.7% during the fourth quarter. Crestwood Advisors Group LLC now owns 2,309 shares of the company's stock worth $225,000 after acquiring an additional 205 shares during the period. Finally, Denali Advisors LLC raised its position in Novartis by 1.9% in the fourth quarter. Denali Advisors LLC now owns 22,112 shares of the company's stock worth $2,152,000 after acquiring an additional 417 shares in the last quarter. Hedge funds and other institutional investors own 13.12% of the company's stock.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.